Spexis AG / Key word(s): Statement Spexis to host business update conference call on October 9, 2023 06.10.2023 / 07:30 CET/CEST
Spexis to host business update conference call on October 9, 2023 Allschwil, Switzerland, October 6, 2023 Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on macrocycle therapeutics for rare diseases and oncology, announced today that it will host a business update conference call on October 9, 2023, at 8.30am EDT. Jeffrey D. Wager, M.D. (CEO & Chairman) will provide strategic business and financial updates. To access the conference call please use the following details: France: +33 0805102207 International Toll Free +1 412-317-6789 Event Title: Spexis AG – Business Update Conference Call The conference call will also be available via webcast: https://event.choruscall.com/mediaframe/webcast.html?webcastid=6s6eCE7g After the call, a replay of the webcast will be available via the above link. About Spexis Spexis (SIX: SPEX) is a clinical-stage biopharmaceutical company based in Allschwil, Switzerland, focused on macrocycle therapeutics for rare diseases and oncology. For further information please visit: www.spexisbio.com.
For further information please contact: For Investors: Or Stephen Jasper
For Media:
End of Media Release |
AbbVie CEO Richard Gonzalez to retire July 1 with Humira transition underway
AbbVie CEO Richard Gonzalez will hand the CEO post to president and COO Robert Michael on July 1 as the Chicago-area Big Pharma progresses through